BEST Inc. Announces Changes to its Board of Directors
/PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China,...
Source: prnewswire.com
Page 9 - Jun Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jun Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jun Chen Today - Breaking & Trending Today
BEST Inc. Announces Changes to its Board of Directors
HANGZHOU, China, Feb. 22, 2022 /PRNewswire/ -- BEST Inc. (NYSE: BEST) ('BEST' or the 'Company'), a leading integrated smart supply chain solutions...
Source: businessinsider.com
BEST Inc. Announces Changes to its Board of Directors
/PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China,...
Source: prnewswire.com
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1...
Source: prnewswire.com
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human immunodeficiency virus (HIV) with antiviral suppression. The objective of this study (ClinicalTrials.gov Identifier: NCT05129189) is to evaluate the...
Source: asiaone.com